Cylene announces evidence for targeting of Pol I as new approach to cancer therapy
The studies were also conducted in in vivo models of blood cancers and confirmed that the drug removed malignant cells from the bloodstream, while allowing normal healthy blood
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.